Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Sold by Granahan Investment Management LLC

Granahan Investment Management LLC cut its position in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 28.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 527,147 shares of the company's stock after selling 211,105 shares during the period. Granahan Investment Management LLC owned about 0.87% of Pliant Therapeutics worth $6,943,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Franklin Resources Inc. increased its holdings in shares of Pliant Therapeutics by 1.5% in the 3rd quarter. Franklin Resources Inc. now owns 1,039,904 shares of the company's stock valued at $11,657,000 after acquiring an additional 14,913 shares during the period. Harbor Capital Advisors Inc. increased its holdings in shares of Pliant Therapeutics by 4.2% in the 4th quarter. Harbor Capital Advisors Inc. now owns 95,801 shares of the company's stock valued at $1,262,000 after acquiring an additional 3,822 shares during the period. Hennion & Walsh Asset Management Inc. increased its holdings in shares of Pliant Therapeutics by 18.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 108,608 shares of the company's stock valued at $1,430,000 after acquiring an additional 16,634 shares during the period. SG Americas Securities LLC increased its holdings in shares of Pliant Therapeutics by 27.2% in the 4th quarter. SG Americas Securities LLC now owns 30,729 shares of the company's stock valued at $405,000 after acquiring an additional 6,579 shares during the period. Finally, R Squared Ltd purchased a new position in shares of Pliant Therapeutics in the 4th quarter valued at $33,000. 97.30% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Cantor Fitzgerald reiterated a "neutral" rating on shares of Pliant Therapeutics in a report on Tuesday, March 4th. Oppenheimer restated a "market perform" rating on shares of Pliant Therapeutics in a research note on Monday, February 10th. JPMorgan Chase & Co. downgraded Pliant Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Monday, February 10th. Wells Fargo & Company dropped their target price on Pliant Therapeutics from $4.00 to $3.00 and set an "equal weight" rating on the stock in a research note on Tuesday, March 4th. Finally, HC Wainwright restated a "neutral" rating on shares of Pliant Therapeutics in a research note on Tuesday, March 18th. Twelve investment analysts have rated the stock with a hold rating, According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $13.31.

Pliant Therapeutics Stock Performance

Shares of PLRX stock traded up $0.01 during mid-day trading on Thursday, reaching $1.37. The stock had a trading volume of 419,882 shares, compared to its average volume of 1,074,508. The business's fifty day moving average is $1.46 and its 200-day moving average is $7.63. The company has a current ratio of 10.26, a quick ratio of 10.26 and a debt-to-equity ratio of 0.09. The firm has a market cap of $84.10 million, a price-to-earnings ratio of -0.41 and a beta of 1.43. Pliant Therapeutics, Inc. has a 1-year low of $1.10 and a 1-year high of $16.10.

Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.82) earnings per share for the quarter, beating analysts' consensus estimates of ($0.99) by $0.17. On average, research analysts forecast that Pliant Therapeutics, Inc. will post -3.64 earnings per share for the current year.

Pliant Therapeutics Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.